6 results on '"Jastaniah, W."'
Search Results
2. Single Dose Oral Dexamethasone in the Emergency Management of Children with Exacerbation of Mild to Moderate Asthma
- Author
-
Altamimi, S., primary, Robertson, G., additional, Jastaniah, W., additional, Davey, A., additional, Dehghani, N., additional, Chen, R., additional, and Colbourne, K. Leung M., additional
- Published
- 2005
- Full Text
- View/download PDF
3. A clinical approach to non-neutropenic fever in children with cancer.
- Author
-
AlAzmi A, Jastaniah W, AlDabbagh M, and Elimam N
- Subjects
- Adolescent, Anti-Bacterial Agents therapeutic use, Bacteremia drug therapy, Bacteremia epidemiology, C-Reactive Protein analysis, Catheter-Related Infections drug therapy, Catheter-Related Infections etiology, Ceftriaxone therapeutic use, Central Venous Catheters adverse effects, Child, Child, Preschool, Disease Management, Female, Humans, Infant, Infant, Newborn, Male, Neutropenia, Respiration Disorders complications, Respiration Disorders therapy, Retrospective Studies, Risk Factors, Fever complications, Fever drug therapy, Neoplasms complications
- Abstract
Background: There are a limited number of studies that address non-neutropenic fever episodes in children with cancer, and no standard approach exists., Method: We opt to retrospectively analyze the efficacy of the current clinical approach for management of non-neutropenic fever episodes and the associated risk factors among children with cancer at the Princess Noorah Oncology Center from May 2016 through December 2017., Results: A total of 480 non-neutropenic fever episodes were identified in 131 children, of which 62 episodes were triaged as high-risk non-neutropenic fever and 418 as low-risk non-neutropenic fever. Of those 480 non-neutropenic fever, 361 episodes (75.2%) were associated with the presence of central venous catheters. The overall failure rate of ceftriaxone mono-therapy was observed in 75.6% (11.7% in high-risk non-neutropenic fever with a mean C-reactive protein level of 21.1 (±23.2) mmol/L and 63.9% in low-risk non-neutropenic fever with a mean C-reactive protein level of 17.6 (±53.9) mmol/L). The overall bacteremia rate was 14.4%. The type of organisms isolated was mainly high-risk organisms in 59 non-neutropenic fever episodes (85.5%), OR 1.78 (95% CI: 0.45-7.04) p = 0.41. Of note, all bacteremia were associated with the presence of central venous catheter (100%). Of all the examined risk factors of outpatient treatment failure in low-risk non-neutropenic fever, only prolonged fever of more than three days were significantly associated with bacteremia OR 8.107 [95% CI: 1.744-37.691], p = 0.008. Noteworthy is that almost 43% of non-neutropenic fever episodes were associated with respiratory symptoms. This study provides a baseline for future prospective research assessing the pattern of non-neutropenic fever by focusing on associated risk factors.
- Published
- 2021
- Full Text
- View/download PDF
4. FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies.
- Author
-
Mustafa O, Abdalla K, AlAzmi AA, Elimam N, Abrar MB, and Jastaniah W
- Subjects
- Adolescent, Bone Marrow Transplantation, Child, Child, Preschool, Cytarabine administration & dosage, Female, Granulocyte Colony-Stimulating Factor administration & dosage, Humans, Idarubicin administration & dosage, Infant, Male, Recurrence, Remission Induction, Retrospective Studies, Vidarabine administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Leukemia, Myeloid, Acute drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Vidarabine analogs & derivatives
- Abstract
Background: Outcomes of relapsed/refractory childhood acute leukemia remain poor. We analyzed the safety/efficacy of fludarabine, cytarabine, and granulocyte colony stimulating factor, with/without idarubicin (FLAG ± IDA) as salvage therapy compared with recent published results of novel therapies., Methods: This retrospective study included children aged 1 to 15 years with relapsed/refractory acute leukemia who received FLAG ± IDA salvage therapy from January 2000 to December 2014. Patients with infant leukemia, mixed lineage leukemia, Philadelphia-positive acute leukemia, or secondary leukemia were excluded., Result: Fifty patients were identified: 25 with acute lymphoblastic leukemia and 25 with acute myeloid leukemia. The median age at initiation of FLAG ± IDA was seven years. Site of relapse was the bone marrow in 29, isolated central nervous system in 11, and combined in 10 patients. FLAG ± IDA was used after first relapse in 68% and after multiple relapses in 32%. Complete remission was achieved in 34 (68%) patients. No variables predictive of complete remission were identified. Grade 3 or greater toxicity was observed in 96% and 6% died from toxicity. Toxicities included hematologic toxicity (96%), infection (52%), and enterocolitis (28%). Twenty-four of 50 (48%) patients achieved a sustained complete remission and survived to bone marrow transplantation. The five-year overall survival was 23.9% ± 6.9%. Patients achieving second complete remission and patients proceeding to bone marrow transplantation following second complete remission demonstrated significantly improved overall survival (p = 0.001)., Conclusion: Despite a 68% complete remission rate using FLAG ± IDA, only 48% of patients survived to bone marrow transplantation. The regimen was associated with 96% toxicity and only one in four patients was alive at five years. This underscores the need to find more effective lower toxicity salvage regimens.
- Published
- 2019
- Full Text
- View/download PDF
5. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
- Author
-
Aseeri M, Mukhtar A, Al Khansa S, Elimam N, and Jastaniah W
- Subjects
- Adolescent, Antineoplastic Agents therapeutic use, Child, Child, Preschool, Cohort Studies, Female, Humans, Infant, Male, Nausea chemically induced, Practice Guidelines as Topic, Quality of Life, Retrospective Studies, Tertiary Care Centers, Vomiting chemically induced, Antiemetics therapeutic use, Antineoplastic Agents adverse effects, Nausea prevention & control, Vomiting prevention & control
- Abstract
Background: Chemotherapy-induced nausea and vomiting are the most dreaded and distressing side effects for cancer patients undergoing chemotherapy treatment. These side effects have a significant impact on the patients' quality of life and can interfere with their ability to receive intensive chemotherapy regimens. With the recent advances in antiemetic pharmacotherapy and supportive care, the current treatments for chemotherapy-induced nausea and vomiting, when used appropriately, have become highly effective in mitigating these adverse effects., Objective: The aim of this study was to evaluate the current practice involving antiemetic treatment in newly diagnosed pediatric oncology patients at our center., Methods: This was a retrospective cohort study of newly diagnosed pediatric oncology patients who were less than 14 years of age receiving their first cycle of inpatient chemotherapy. The data abstracted included the following: age, gender, type of cancer, chemotherapy regimen, emetogenic risk and level, prescribed prophylactic antiemetic regimen, incidence of breakthrough emesis, and breakthrough antiemetic medications used. Emetogenic risk was classified based on published guidelines into low, moderate, or high emetogenic chemotherapy, and a scoring system to determine the emetogenic level of combined chemotherapy agents was followed to monitor the efficacy of the antiemetic regimens. Clinical effectiveness was assessed based on breakthrough emesis., Results: A total of 49 patients were eligible for the study. High emetogenic chemotherapy was administered in 28/49 (57.1%) and moderate emetogenic chemotherapy was administered in 21/49 (42.9%) patients. Only 10/49 (20.4%) received appropriate antiemetic prophylaxis, whereas 39/49 (79.6%) received inadequate antiemetic prophylaxis; 14/49 (28.6%) patients experienced breakthrough emesis. Breakthrough emesis occurred in 11/28 (39.3%) patients receiving high emetogenic chemotherapy and 3/21 (14.3%) patients receiving moderate emetogenic chemotherapy. The use of an inadequate antiemetic regimen was found in 14/14 (100%) patients with breakthrough emesis. Thus, inadequate prophylaxis resulted in a 35.9% (14/39) risk of breakthrough emesis. This risk was higher in patients receiving high emetogenic chemotherapy versus those receiving moderate emetogenic chemotherapy (39.3% versus 14.3%)., Conclusion: Inadequate antiemetic prophylaxis is associated with a high risk of breakthrough emesis particularly with high emetogenic chemotherapy regimens. Standardizing antiemetic prophylaxis based on emetogenic level could reduce breakthrough emesis and improve the quality of life in pediatric oncology patients.
- Published
- 2013
- Full Text
- View/download PDF
6. A cross-sectional study comparing variation in body surface area and chemotherapy dosing in pediatric oncology using two different methods.
- Author
-
Jastaniah W and Aseeri M
- Subjects
- Algorithms, Anthropometry, Antineoplastic Agents therapeutic use, Child, Child, Preschool, Cross-Sectional Studies, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Neoplasms drug therapy, Antineoplastic Agents administration & dosage, Body Surface Area, Body Weight
- Abstract
Purpose: Standardizing body surface area (BSA) determination is essential for avoiding variation in chemotherapy dosage calculations. In this study, we compared variation in BSA calculation using weight and height by the Mosteller formula with weight alone using recently adapted table at a local oncology center., Methods: Cross-sectional study of pediatric oncology patients presenting to a pediatric oncology clinic over a week period of time., Results: One-hundred consecutive pediatric oncology patients presented to the clinic. The mean BSA calculated by the Mosteller formula was 0.83 m(2) (SD 0.24) and the mean BSA determined by the table (based on weight alone) was 0.82 m(2) (SD 0.25). The mean variation in dosing between the two methods was 1.64% (SD 3.4). Only 13 out of 100 patients (13%) had equal dosing using both methods and 21 out of 100 patients (21%) had dosing variation greater than 5%. When comparing both methods, using paired t-test, the difference was statistically significant (t((99)) = 3.99 and p < 0.001)., Conclusion: Significant differences in BSAbased chemotherapy dosing exist in our center. The Mosteller method should remain the standard until prospective studies are performed to determine the significance of this dosing variability on toxicity and survival outcome.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.